SCHEMBL30294397

SCHEMBL30294397

Cc1cc(F)ccc1Nc1ccc(Cl)cc1C(=O)O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.54
HSD17B10 Q99714 1/20 0.54
FABP3 P05413 2/20 0.51
FABP4 P15090 2/20 0.51
P2RY4 P51582 1/20 0.51
MAPT P10636 2/20 0.49
KMT2A Q03164 2/20 0.49
FTO Q9C0B1 1/20 0.49
ALDH1A1 P00352 1/20 0.49
CLCN2 P51788 1/20 0.49
MPO P05164 1/20 0.49
MAPK13 O15264 1/20 0.48
MAPK12 P53778 1/20 0.48
MAPK11 Q15759 1/20 0.48
MAPK14 Q16539 1/20 0.48
AKR1C3 P42330 1/20 0.47
AKR1C2 P52895 1/20 0.47
KCNH2 Q12809 1/20 0.46
GRIK1 P39086 1/20 0.46
MEN1 O00255 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22852993 1.00 KDM4E (0.54) KDM4EHSD17B10FABP3FABP4P2RY4
SCHEMBL22852841 0.90 CLCN2 (0.57) KDM4EHSD17B10FABP3FABP4MAPT
SCHEMBL30294548 0.90 CLCN2 (0.57) KDM4EHSD17B10FABP3FABP4MAPT
SCHEMBL22853383 0.90 P2RY4 (0.56) FABP3FABP4P2RY4KMT2AFTO
SCHEMBL30294653 0.90 P2RY4 (0.56) FABP3FABP4P2RY4KMT2AFTO
SCHEMBL31521818 0.86 KMT2A (0.53) MAPTKMT2AALDH1A1MAPK13MAPK12
SCHEMBL22852994 0.85 DHODH (0.56) FABP3FABP4P2RY4KMT2AAKR1C3
SCHEMBL30294529 0.85 DHODH (0.56) FABP3FABP4P2RY4KMT2AAKR1C3
SCHEMBL22853082 0.83 CLCN2 (0.53) FABP3FABP4P2RY4MAPTFTO
SCHEMBL22853345 0.83 KDM4E (0.51) KDM4EHSD17B10FABP3FABP4P2RY4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250084112-A1 Chemical Compounds Useful for Inhibiting Nav1.8 Voltage-Gated Sodium Channels and Treating Nav1.8 Mediated Diseases GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2025-03-13 US disclosed
US-20230103791-A1 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2023-04-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250084112-A1 Chemical Compounds Useful for Inhibiting Nav1.8 Voltage-Gated Sodium Channels and Treating Nav1.8 Mediated Diseases SCN8A, SCN1A, SCN10A KDM4E 3090/4885HSD17B10 1950/4885FABP3 514/4885
US-20230103791-A1 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS SCN8A, SCN1A, SCN1B KDM4E 3392/4885HSD17B10 4145/4885FABP3 2946/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.